Interventional Spine Inc Opticage

Register for a free U.S. Market for Spinal Implants and VCF brochure or synopsis

Interventional Spine, Inc. announced the launch of a new line of products that will be showcased at this year’s International Society for the Advancement of Spine Surgery (ISASS) Annual Meeting in Las Vegas, NV. The new products include recent size additions to the Opticage® Lumbar Fusion line of spine products, as well as lordotic versions of the interbody device.

“We are proud to introduce this year’s line-up of new minimally invasive spine products at ISASS and provide an opportunity for surgeons to see a demonstration of the new products,” said Joseph Darling, Interventional Spine’s Chief Operating Officer. “These new and innovative devices, which build upon our existing line of products, are designed to assist surgeons in delivering superior patient outcomes in an affordable manner for Lumbar Fusion Surgery. Important to note is that this latest generation of the Opticage is derived from, and uses the same basic mechanism, as the original Opticage expandable which has been used in over 2,500 clinical cases. We look forward to showcasing their benefits at the ISASS meeting.”

The new Opticage G3 product features include the following:

  • Superior Expansion Strength (1600N)
  • Support for Multiple Surgical Approaches including PLIF, TLIF and Lateral
  • Intraoperative Flexibility
  • Significant Graft Window Size
  • Lateral and TLIF designs for parallel and lordotic applications
  • OptiGraft Inserter
  • Offers opportunity to fill the Opticage with additional flowable graft material post expansion in situ

About Interventional Spine, Inc.
Interventional Spine, Inc. is a privately held company based in Irvine, California, that designs, develops, and markets patented implantable devices for the spine that can be deployed via both surgical and minimally invasive techniques. Supported by the Company’s unique product introduction systems, Interventional Spine’s products provide benefits to patients, surgeons, and healthcare facilities alike. For more information on the Company and its products, please refer to their website at:

For Further Information
More on the spinal implant market can be found in the report published by iData entitled U.S. Market for Spinal Implants & Vertebral Compression Fractures. This report covers the U.S. and includes the following market segments: cervical fixation, thoracolumbar fixation, interbody devices, motion preservation devices, vertebral compression fractures, and spinal electrical stimulation.

The global series on the spinal implant and VCF markets covers the U.S., Australia, Japan, South Korea, China, Taiwan, and 15 countries in Europe. Full reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. Register online or email us at [email protected] for a U.S. Market for Spinal Implants and VCF report brochure and synopsis.

About Procedure Tracker
Procedure number data is available from iData’s Procedure Tracker service, which allows subscribers to define and analyze procedure data segmented by state, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.

About Reimbursement Tracker
iData Research’s Reimbursement Policy Tracker enables medical device, dental, pharmaceutical and healthcare professionals to receive real-time policy updates from hundreds of insurance companies and 60,000+ policies across all therapeutic areas in the United States.

Explore our careers page for our current available job opportunities. This is your chance to join a fun and dynamic team in the medical market research industry. Send your resume to [email protected] with the job title in the subject line, and feel free to tell us a little about yourself. We look forward to hearing from you.

Like us on Facebook:
Follow us on LinkedIn:
Follow us on Twitter: